|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RBM15B |
Gene summary for RBM15B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RBM15B | Gene ID | 29890 |
| Gene name | RNA binding motif protein 15B | |
| Gene Alias | HUMAGCGB | |
| Cytomap | 3p21.2 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q8NDT2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29890 | RBM15B | P74T-E | Human | Esophagus | ESCC | 5.73e-11 | 8.25e-02 | 0.1479 |
| 29890 | RBM15B | P75T-E | Human | Esophagus | ESCC | 6.41e-12 | 9.68e-02 | 0.1125 |
| 29890 | RBM15B | P76T-E | Human | Esophagus | ESCC | 8.69e-10 | 1.65e-02 | 0.1207 |
| 29890 | RBM15B | P79T-E | Human | Esophagus | ESCC | 7.02e-04 | 9.06e-02 | 0.1154 |
| 29890 | RBM15B | P80T-E | Human | Esophagus | ESCC | 1.25e-16 | 5.02e-01 | 0.155 |
| 29890 | RBM15B | P83T-E | Human | Esophagus | ESCC | 1.18e-09 | 2.20e-01 | 0.1738 |
| 29890 | RBM15B | P89T-E | Human | Esophagus | ESCC | 2.33e-06 | 1.90e-01 | 0.1752 |
| 29890 | RBM15B | P91T-E | Human | Esophagus | ESCC | 8.96e-04 | 2.46e-01 | 0.1828 |
| 29890 | RBM15B | P107T-E | Human | Esophagus | ESCC | 5.13e-14 | 2.03e-01 | 0.171 |
| 29890 | RBM15B | P127T-E | Human | Esophagus | ESCC | 9.21e-11 | 5.54e-02 | 0.0826 |
| 29890 | RBM15B | P128T-E | Human | Esophagus | ESCC | 2.18e-18 | 7.30e-01 | 0.1241 |
| 29890 | RBM15B | P130T-E | Human | Esophagus | ESCC | 9.73e-24 | 4.52e-01 | 0.1676 |
| 29890 | RBM15B | HCC1_Meng | Human | Liver | HCC | 4.00e-39 | 5.16e-02 | 0.0246 |
| 29890 | RBM15B | HCC2_Meng | Human | Liver | HCC | 3.26e-08 | 1.41e-03 | 0.0107 |
| 29890 | RBM15B | cirrhotic2 | Human | Liver | Cirrhotic | 2.31e-04 | 1.03e-01 | 0.0201 |
| 29890 | RBM15B | cirrhotic3 | Human | Liver | Cirrhotic | 4.65e-03 | 8.13e-02 | 0.0215 |
| 29890 | RBM15B | HCC1 | Human | Liver | HCC | 2.05e-04 | 3.50e+00 | 0.5336 |
| 29890 | RBM15B | HCC2 | Human | Liver | HCC | 1.14e-15 | 3.25e+00 | 0.5341 |
| 29890 | RBM15B | Pt13.b | Human | Liver | HCC | 2.09e-10 | 1.59e-01 | 0.0251 |
| 29890 | RBM15B | Pt14.a | Human | Liver | HCC | 3.34e-02 | 2.03e-01 | 0.0169 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
| GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
| GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
| GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
| GO:1903311 | Colorectum | AD | regulation of mRNA metabolic process | 117/3918 | 288/18723 | 1.69e-14 | 4.23e-12 | 117 |
| GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
| GO:0048024 | Colorectum | AD | regulation of mRNA splicing, via spliceosome | 50/3918 | 101/18723 | 1.62e-10 | 1.56e-08 | 50 |
| GO:0050684 | Colorectum | AD | regulation of mRNA processing | 61/3918 | 137/18723 | 4.23e-10 | 3.58e-08 | 61 |
| GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0006403 | Colorectum | AD | RNA localization | 71/3918 | 201/18723 | 1.54e-06 | 4.76e-05 | 71 |
| GO:0000380 | Colorectum | AD | alternative mRNA splicing, via spliceosome | 33/3918 | 77/18723 | 1.13e-05 | 2.55e-04 | 33 |
| GO:0051236 | Colorectum | AD | establishment of RNA localization | 58/3918 | 166/18723 | 1.95e-05 | 4.01e-04 | 58 |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:0050657 | Colorectum | AD | nucleic acid transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0050658 | Colorectum | AD | RNA transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0000381 | Colorectum | AD | regulation of alternative mRNA splicing, via spliceosome | 27/3918 | 60/18723 | 2.41e-05 | 4.66e-04 | 27 |
| GO:0051168 | Colorectum | AD | nuclear export | 53/3918 | 154/18723 | 6.89e-05 | 1.11e-03 | 53 |
| GO:0051028 | Colorectum | AD | mRNA transport | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
| GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RBM15B | SNV | Missense_Mutation | c.2207N>G | p.Ser736Cys | p.S736C | Q8NDT2 | protein_coding | deleterious(0.02) | benign(0.029) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| RBM15B | SNV | Missense_Mutation | rs368511938 | c.1679N>A | p.Arg560Gln | p.R560Q | Q8NDT2 | protein_coding | deleterious(0.03) | probably_damaging(0.95) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| RBM15B | SNV | Missense_Mutation | novel | c.2349C>G | p.Ile783Met | p.I783M | Q8NDT2 | protein_coding | deleterious(0.03) | probably_damaging(0.977) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
| RBM15B | SNV | Missense_Mutation | c.2135N>T | p.Ser712Leu | p.S712L | Q8NDT2 | protein_coding | tolerated(0.07) | benign(0.436) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RBM15B | SNV | Missense_Mutation | rs782106242 | c.1480N>A | p.Glu494Lys | p.E494K | Q8NDT2 | protein_coding | tolerated(0.07) | benign(0.438) | TCGA-E2-A9RU-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | arimidex | SD |
| RBM15B | SNV | Missense_Mutation | novel | c.2325G>T | p.Lys775Asn | p.K775N | Q8NDT2 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-S3-AA10-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | CR |
| RBM15B | SNV | Missense_Mutation | rs782554512 | c.1255C>T | p.Arg419Cys | p.R419C | Q8NDT2 | protein_coding | deleterious(0.04) | possibly_damaging(0.708) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RBM15B | SNV | Missense_Mutation | novel | c.1555C>T | p.Arg519Trp | p.R519W | Q8NDT2 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| RBM15B | SNV | Missense_Mutation | novel | c.1712N>A | p.Arg571His | p.R571H | Q8NDT2 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-A6-2678-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
| RBM15B | SNV | Missense_Mutation | rs372043035 | c.1729C>T | p.Arg577Cys | p.R577C | Q8NDT2 | protein_coding | deleterious(0.03) | probably_damaging(0.913) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |